share_log

Canaccord Genuity Initiates Coverage On Passage Bio With Buy Rating, Announces Price Target of $8

Canaccord Genuity Initiates Coverage On Passage Bio With Buy Rating, Announces Price Target of $8

Canaccord Genuity以買入評級啓動對Passage Bio的報道,宣佈目標股價爲8美元
Benzinga Real-time News ·  2022/11/08 05:02

Canaccord Genuity analyst Whitney Ijem initiates coverage on Passage Bio (NASDAQ:PASG) with a Buy rating and announces Price Target of $8.

Canaccord Genuity分析師惠特尼·伊傑姆以買入評級開始對Passage Bio(納斯達克股票代碼:PASG)進行報道,並宣佈目標股價爲8美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論